Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Another critical focus is on the burden of respiratory syncytial virus (RSV) in young children. A systematic analysis revealed that RSV is a leading cause of acute lower respiratory infections in ...

As new viruses like COVID-19, bird flu, norovirus, and RSV (respiratory syncytial virus) continue to spread, vaccines have ...

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the ...

there are now some very real concerns about a lesser-known virus – respiratory syncytial virus, or RSV. 1 Although RSV can affect both adults and infants, the majority of general awareness and ...

Four flu deaths and three COVID-19 deaths were reported in the state last week, according to the Arkansas Department of ...

A large study of Veterans Affairs (VA) patients in JAMA Internal Medicine shows that, during the 2022 to 2023 season, having ...

The U.S. health sector is on the brink of a transformative era. From the Food and Drug Administration’s (FDA) groundbreaking ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting ... in efforts to reduce the burden of RSV-related disease.

Under the Ministry’s new program, all newborns and babies born after January 1, 2024, became eligible for free immunizations, ...